Cargando…

Management of Hypertension Using Olmesartan Alone or in Combination

Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hyper...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoshen, Zhang, Han, Ma, Yuxia, Che, Wenliang, Hamblin, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446820/
https://www.ncbi.nlm.nih.gov/pubmed/28258390
http://dx.doi.org/10.1007/s40119-017-0087-5
_version_ 1783239172667998208
author Zhang, Xiaoshen
Zhang, Han
Ma, Yuxia
Che, Wenliang
Hamblin, Michael R.
author_facet Zhang, Xiaoshen
Zhang, Han
Ma, Yuxia
Che, Wenliang
Hamblin, Michael R.
author_sort Zhang, Xiaoshen
collection PubMed
description Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients.
format Online
Article
Text
id pubmed-5446820
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-54468202017-06-13 Management of Hypertension Using Olmesartan Alone or in Combination Zhang, Xiaoshen Zhang, Han Ma, Yuxia Che, Wenliang Hamblin, Michael R. Cardiol Ther Review Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients. Springer Healthcare 2017-03-03 2017-06 /pmc/articles/PMC5446820/ /pubmed/28258390 http://dx.doi.org/10.1007/s40119-017-0087-5 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Zhang, Xiaoshen
Zhang, Han
Ma, Yuxia
Che, Wenliang
Hamblin, Michael R.
Management of Hypertension Using Olmesartan Alone or in Combination
title Management of Hypertension Using Olmesartan Alone or in Combination
title_full Management of Hypertension Using Olmesartan Alone or in Combination
title_fullStr Management of Hypertension Using Olmesartan Alone or in Combination
title_full_unstemmed Management of Hypertension Using Olmesartan Alone or in Combination
title_short Management of Hypertension Using Olmesartan Alone or in Combination
title_sort management of hypertension using olmesartan alone or in combination
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446820/
https://www.ncbi.nlm.nih.gov/pubmed/28258390
http://dx.doi.org/10.1007/s40119-017-0087-5
work_keys_str_mv AT zhangxiaoshen managementofhypertensionusingolmesartanaloneorincombination
AT zhanghan managementofhypertensionusingolmesartanaloneorincombination
AT mayuxia managementofhypertensionusingolmesartanaloneorincombination
AT chewenliang managementofhypertensionusingolmesartanaloneorincombination
AT hamblinmichaelr managementofhypertensionusingolmesartanaloneorincombination